Exercise improves quality of life in androgen deprivation therapy treated prostate cancer: Systematic review of randomised controlled trials

Laisa Teleni, Raymond J. Chan, Alexandre Chan, Elisabeth A. Isenring, Ian Vela, Warrick J. Inder, Alexandra L. McCarthy

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)

Abstract

Men receiving androgen deprivation therapy (ADT) for prostate cancer (PCa) are likely to develop metabolic conditions such as diabetes, cardiovascular disease, abdominal obesity and osteoporosis. Other treatment-related side effects adversely influence quality of life (QoL) including vasomotor distress, depression, anxiety, mood swings, poor sleep quality and compromised sexual function. The objective of this study was to systematically review the nature and effects of dietary and exercise interventions on QoL, androgen deprivation symptoms and metabolic risk factors in men with PCa undergoing ADT. An electronic search of CINAHL, CENTRAL, Medline, PsychINFO and reference lists was performed to identify peerreviewed articles published between January 2004 and December 2014 in English. Eligible study designs included randomised controlled trials (RCTs) with pre- and post-intervention data. Data extraction and assessment of methodological quality with the Cochrane approach was conducted by two independent reviewers. Seven exercise studies were identified. Exercise significantly improved QoL, but showed no effect on metabolic risk factors (weight, waist circumference, lean or fat mass, blood pressure and lipid profile). Two dietary studies were identified, both of which tested soy supplements. Soy supplementation did not improve any outcomes. No dietary counselling studies were identified. No studies evaluated androgen-deficiency symptoms (libido, erectile function, sleep quality, mood swings, depression, anxiety and bone mineral density). Evidence from RCTs indicates that exercise enhances health- and disease-specific QoL in men with PCa undergoing ADT. Further studies are required to evaluate the effect of exercise and dietary interventions on QoL, androgen deprivation symptoms and metabolic risk factors in this cohort.

Original languageEnglish
Pages (from-to)101-112
Number of pages12
JournalEndocrine-Related Cancer
Volume23
Issue number2
DOIs
Publication statusPublished - 1 Feb 2016

Fingerprint

Androgens
Prostatic Neoplasms
Randomized Controlled Trials
Quality of Life
Exercise
Sleep
Therapeutics
Anxiety
Depression
Libido
Abdominal Obesity
Waist Circumference
Bone Density
Osteoporosis
Counseling
Cardiovascular Diseases
Fats
Blood Pressure
Lipids
Weights and Measures

Cite this

Teleni, Laisa ; Chan, Raymond J. ; Chan, Alexandre ; Isenring, Elisabeth A. ; Vela, Ian ; Inder, Warrick J. ; McCarthy, Alexandra L. / Exercise improves quality of life in androgen deprivation therapy treated prostate cancer: Systematic review of randomised controlled trials. In: Endocrine-Related Cancer. 2016 ; Vol. 23, No. 2. pp. 101-112.
@article{efcdff7e1ead441bacf2cd0af594f8d4,
title = "Exercise improves quality of life in androgen deprivation therapy treated prostate cancer: Systematic review of randomised controlled trials",
abstract = "Men receiving androgen deprivation therapy (ADT) for prostate cancer (PCa) are likely to develop metabolic conditions such as diabetes, cardiovascular disease, abdominal obesity and osteoporosis. Other treatment-related side effects adversely influence quality of life (QoL) including vasomotor distress, depression, anxiety, mood swings, poor sleep quality and compromised sexual function. The objective of this study was to systematically review the nature and effects of dietary and exercise interventions on QoL, androgen deprivation symptoms and metabolic risk factors in men with PCa undergoing ADT. An electronic search of CINAHL, CENTRAL, Medline, PsychINFO and reference lists was performed to identify peerreviewed articles published between January 2004 and December 2014 in English. Eligible study designs included randomised controlled trials (RCTs) with pre- and post-intervention data. Data extraction and assessment of methodological quality with the Cochrane approach was conducted by two independent reviewers. Seven exercise studies were identified. Exercise significantly improved QoL, but showed no effect on metabolic risk factors (weight, waist circumference, lean or fat mass, blood pressure and lipid profile). Two dietary studies were identified, both of which tested soy supplements. Soy supplementation did not improve any outcomes. No dietary counselling studies were identified. No studies evaluated androgen-deficiency symptoms (libido, erectile function, sleep quality, mood swings, depression, anxiety and bone mineral density). Evidence from RCTs indicates that exercise enhances health- and disease-specific QoL in men with PCa undergoing ADT. Further studies are required to evaluate the effect of exercise and dietary interventions on QoL, androgen deprivation symptoms and metabolic risk factors in this cohort.",
author = "Laisa Teleni and Chan, {Raymond J.} and Alexandre Chan and Isenring, {Elisabeth A.} and Ian Vela and Inder, {Warrick J.} and McCarthy, {Alexandra L.}",
note = "{\circledC} 2016 Society for Endocrinology.",
year = "2016",
month = "2",
day = "1",
doi = "10.1530/ERC-15-0456",
language = "English",
volume = "23",
pages = "101--112",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "BioScientifica Ltd.",
number = "2",

}

Exercise improves quality of life in androgen deprivation therapy treated prostate cancer: Systematic review of randomised controlled trials. / Teleni, Laisa; Chan, Raymond J.; Chan, Alexandre; Isenring, Elisabeth A.; Vela, Ian; Inder, Warrick J.; McCarthy, Alexandra L.

In: Endocrine-Related Cancer, Vol. 23, No. 2, 01.02.2016, p. 101-112.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Exercise improves quality of life in androgen deprivation therapy treated prostate cancer: Systematic review of randomised controlled trials

AU - Teleni, Laisa

AU - Chan, Raymond J.

AU - Chan, Alexandre

AU - Isenring, Elisabeth A.

AU - Vela, Ian

AU - Inder, Warrick J.

AU - McCarthy, Alexandra L.

N1 - © 2016 Society for Endocrinology.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Men receiving androgen deprivation therapy (ADT) for prostate cancer (PCa) are likely to develop metabolic conditions such as diabetes, cardiovascular disease, abdominal obesity and osteoporosis. Other treatment-related side effects adversely influence quality of life (QoL) including vasomotor distress, depression, anxiety, mood swings, poor sleep quality and compromised sexual function. The objective of this study was to systematically review the nature and effects of dietary and exercise interventions on QoL, androgen deprivation symptoms and metabolic risk factors in men with PCa undergoing ADT. An electronic search of CINAHL, CENTRAL, Medline, PsychINFO and reference lists was performed to identify peerreviewed articles published between January 2004 and December 2014 in English. Eligible study designs included randomised controlled trials (RCTs) with pre- and post-intervention data. Data extraction and assessment of methodological quality with the Cochrane approach was conducted by two independent reviewers. Seven exercise studies were identified. Exercise significantly improved QoL, but showed no effect on metabolic risk factors (weight, waist circumference, lean or fat mass, blood pressure and lipid profile). Two dietary studies were identified, both of which tested soy supplements. Soy supplementation did not improve any outcomes. No dietary counselling studies were identified. No studies evaluated androgen-deficiency symptoms (libido, erectile function, sleep quality, mood swings, depression, anxiety and bone mineral density). Evidence from RCTs indicates that exercise enhances health- and disease-specific QoL in men with PCa undergoing ADT. Further studies are required to evaluate the effect of exercise and dietary interventions on QoL, androgen deprivation symptoms and metabolic risk factors in this cohort.

AB - Men receiving androgen deprivation therapy (ADT) for prostate cancer (PCa) are likely to develop metabolic conditions such as diabetes, cardiovascular disease, abdominal obesity and osteoporosis. Other treatment-related side effects adversely influence quality of life (QoL) including vasomotor distress, depression, anxiety, mood swings, poor sleep quality and compromised sexual function. The objective of this study was to systematically review the nature and effects of dietary and exercise interventions on QoL, androgen deprivation symptoms and metabolic risk factors in men with PCa undergoing ADT. An electronic search of CINAHL, CENTRAL, Medline, PsychINFO and reference lists was performed to identify peerreviewed articles published between January 2004 and December 2014 in English. Eligible study designs included randomised controlled trials (RCTs) with pre- and post-intervention data. Data extraction and assessment of methodological quality with the Cochrane approach was conducted by two independent reviewers. Seven exercise studies were identified. Exercise significantly improved QoL, but showed no effect on metabolic risk factors (weight, waist circumference, lean or fat mass, blood pressure and lipid profile). Two dietary studies were identified, both of which tested soy supplements. Soy supplementation did not improve any outcomes. No dietary counselling studies were identified. No studies evaluated androgen-deficiency symptoms (libido, erectile function, sleep quality, mood swings, depression, anxiety and bone mineral density). Evidence from RCTs indicates that exercise enhances health- and disease-specific QoL in men with PCa undergoing ADT. Further studies are required to evaluate the effect of exercise and dietary interventions on QoL, androgen deprivation symptoms and metabolic risk factors in this cohort.

UR - http://www.scopus.com/inward/record.url?scp=84984537611&partnerID=8YFLogxK

U2 - 10.1530/ERC-15-0456

DO - 10.1530/ERC-15-0456

M3 - Article

VL - 23

SP - 101

EP - 112

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 2

ER -